XTX Topco Ltd Buys 33,651 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

XTX Topco Ltd increased its position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 37.1% during the second quarter, HoldingsChannel.com reports. The firm owned 124,301 shares of the company’s stock after acquiring an additional 33,651 shares during the quarter. XTX Topco Ltd’s holdings in Poseida Therapeutics were worth $363,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in Poseida Therapeutics in the fourth quarter worth about $36,000. Cantor Fitzgerald L. P. bought a new stake in shares of Poseida Therapeutics during the fourth quarter valued at approximately $169,000. Russell Investments Group Ltd. bought a new stake in shares of Poseida Therapeutics during the first quarter valued at approximately $110,000. Blair William & Co. IL raised its holdings in Poseida Therapeutics by 41.3% in the 1st quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock worth $3,079,000 after acquiring an additional 282,310 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Poseida Therapeutics by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after acquiring an additional 473,746 shares in the last quarter. 46.87% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Poseida Therapeutics in a research note on Tuesday, August 6th.

Poseida Therapeutics Stock Performance

Shares of NASDAQ PSTX opened at $2.97 on Friday. The firm’s 50-day moving average price is $3.09 and its 200-day moving average price is $2.94. Poseida Therapeutics, Inc. has a 52-week low of $1.83 and a 52-week high of $4.27. The company has a market cap of $288.48 million, a PE ratio of -2.52 and a beta of 0.51. The company has a quick ratio of 2.48, a current ratio of 2.48 and a debt-to-equity ratio of 0.97.

Poseida Therapeutics (NASDAQ:PSTX) last issued its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. The company had revenue of $25.97 million for the quarter, compared to analysts’ expectations of $13.75 million. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. As a group, analysts anticipate that Poseida Therapeutics, Inc. will post -1.57 EPS for the current year.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.